Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Completed 2Withdrawn 1

Sponsor Class

OTHER 21NETWORK 3INDUSTRY 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 3

Conditions

Multiple Myeloma 45Precursor Cell Lymphoblastic Leukemia-Lymphoma 20Leukemia 19Lymphoma 15Burkitt Lymphoma 8Neoplasms, Plasma Cell 5Hodgkin Disease 5Recurrence 4Leukemia, Biphenotypic, Acute 4Immunoglobulin Light-chain Amyloidosis 4Waldenstrom Macroglobulinemia 3Lymphoma, Large B-Cell, Diffuse 3Lung Neoplasms 3Vomiting 2Prostatic Neoplasms 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 2Nausea 2Lymphoma, Mantle-Cell 2Lymphoma, Large-Cell, Anaplastic 2Disease 2Carcinoma, Non-Small-Cell Lung 2Uterine Cervical Neoplasms 1Thrombocytopenia 1Stomach Neoplasms 1Smoldering Multiple Myeloma 1Seminoma 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Oligodendroglioma 1

Interventions

Doxorubicin 4Cyclophosphamide 4Vincristine 3Rituximab 3Prednisone 3Dexamethasone 3Radiotherapy 2Peripheral Blood Stem Cell Transplantation 2Melphalan 2Interferon-alpha 2Etoposide 2Cytarabine 2Bortezomib 2tositumomab I-131 1liposomal amphotericin B 1fludarabine 1denileukin diftitox 1Watchful Waiting 1Vancomycin 1VAP-cyclo protocol 1Thalidomide 1Tazobactam 1Piperacillin, Tazobactam Drug Combination 1Piperacillin 1Palliative Care 1Nutritional Support 1Moxifloxacin 1Morphine 1Methotrexate 1Lapatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
NETWORK × Waldenstrom Macroglobulinemia × Dexamethasone × Clear all
NCT00003416 2015-03-06

S9805, High-Dose Melphalan Plus Peripheral Stem Cell Transplantation Followed by Interferon Alfa in Treating Patients With Waldenstrom's Macroglobulinemia

SWOG Cancer Research Network

Phase 2 Completed
9 enrolled
Lymphoid

Lymphoma, Waldenstrom Macroglobulinemia

NCT00723658 2015-03-06

S0629, Observation or Combination Chemotherapy, Bortezomib, Thalidomide, and Rituximab Followed By Two Autologous Peripheral Blood Stem Cell Transplants in Treating Patients With Waldenstrom Macroglobulinemia

SWOG Cancer Research Network

Phase 2 Withdrawn
Lymphoid

Lymphoma, Waldenstrom Macroglobulinemia

NCT00832234 2015-02-18

BDR-WM

European Myeloma Network B.V.

Phase 2 Completed
59 enrolled
Lymphoid

Waldenstrom Macroglobulinemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡